FDMT vs BMRN โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
BMRN Captures Institutional Edge (3โ1 Pillars ยท 8โ2 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to BioMarin Pharmaceuticals Inc (BMRN) driven by superior Valuation, Growth & Margin, Options & Structure while FDMT counters with relative strength in Momentum & Technical. Fundamentally, FDMT trades at N/M Forward P/E with -222.7% operating margin (+4505.6% YoY revenue) versus BMRN at 9.1x Forward P/E and 16.3% operating margin (+32.0% YoY). In options structure, FDMT sits in BREAKDOWN (10th %ile IV; Dealer Gamma Walls on Pro) against BMRN sits in CONSOLIDATION (17th %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | FDMT Revenue | BMRN Revenue | FDMT Op. Margin | BMRN Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2018 | N/A | $1.49B | N/A | -8.3% | BMRN |
| FY2019 | $10M | $1.70B | -729.4% | -5.9% | BMRN |
| FY2020 | $10M | $1.86B | -424.0% | -2.3% | BMRN |
| FY2021 | $20M | $1.85B | -395.5% | -4.5% | BMRN |
| FY2022 | $0M | $2.10B | -3516.5% | 7.7% | BMRN |
| FY2023 | $20M | $2.42B | -544.6% | 7.7% | BMRN |
| FY2024 | $0M | $2.85B | -507678.4% | 17.0% | BMRN |
| FY2025 | $90M | $3.22B | -187.2% | 12.7% | BMRN |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | FDMT | BMRN | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $669.3M | $11.0B | Larger Scale | BMRN |
| Trailing P/E Ratio Valuation | N/M | 8.8x | Lower Multiple | BMRN |
| Forward P/E Ratio Valuation | N/M | 9.1x | Lower Multiple | BMRN |
| Revenue Growth (YoY) Growth | +4505.6% | +32.0% | Higher Growth | FDMT |
| Operating Margin (TTM) Profitability | -222.7% | 16.3% | Higher Margin | BMRN |
| Net Profit Margin Profitability | -208.6% | -0.5% | Higher Margin | BMRN |
| Return on Equity (ROE) Capital Efficiency | -56.7% | -0.3% | Higher ROE | BMRN |
| 52-Week Range Position Momentum | 47% ($7โ$17) | 42% ($49โ$71) | Stronger Trend | FDMT |
| Beta / 30D Volatility Risk Regime | 1.89ฮฒ ยท 90% Vol | 0.28ฮฒ ยท 31% Vol | Lower Realized Risk | BMRN |
| Unified Institutional Score Composite Signal | 42.1 / 100 (HOLD) | 52.3 / 100 (HOLD) | Higher Composite | BMRN |